Clinical trial
Vaccine Therapy in Treating Patients With Melanoma
NCT00003556 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003556 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Melanoma |
| Official title | Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With Surgically Incurable Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | ALVAC-hB7.1, canarypox-hIL-12 melanoma vaccine |
| Enrollment | 15 |
| Start date | Jan 1, 1999 |
| Primary completion | May 1, 2001 |
| First posted | Aug 17, 2004 |
| Last update posted | Feb 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: